Search research articles
Contact Us
Filters
Showing results (41-50 of 434) with videos related to
Page
of 44
Sort By:
Best Practice & Research. Clinical Endocrinology & Metabolism
|
September 15, 2009
The spectrum of antidiabetic actions of GLP-1 in patients with diabetes
Tina Vilsbøll, Jens J Holst, Filip K Knop
Expert Opinion on Drug Metabolism & Toxicology
|
October 26, 2012
GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations
Maria J Jespersen, Filip K Knop, Mikkel Christensen
Current Opinion in Endocrinology, Diabetes, and Obesity
|
January 23, 2022
Long-acting amylin analogues for the management of obesity
David S Mathiesen, Jonatan I Bagger, Filip K Knop
The Journal of Clinical Endocrinology and Metabolism
|
August 24, 2018
New Avenues in the Regulation of Gallbladder Motility-Implications for the Use of Glucagon-Like Peptide-Derived Drugs
Ida M Gether, Christina Nexøe-Larsen, Filip K Knop
Mayo Clinic Proceedings
|
January 9, 2018
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Sofie Hædersdal, Asger Lund, Filip K Knop, et al.
Nature Reviews. Endocrinology
|
May 6, 2018
Glucagon-like peptide 1 in health and disease
Andreas Andersen, Asger Lund, Filip K Knop, et al.
Nature Reviews. Endocrinology
|
March 18, 2023
Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases
Sofie Hædersdal, Andreas Andersen, Filip K Knop, et al.
Frontiers in Endocrinology
|
December 3, 2021
Editorial: Proglucagon-Derived Peptides
Peter R Flatt, Filip K Knop, Andrei I Tarasov
International Journal of Molecular Sciences
|
August 10, 2024
Comment on Yang et al. Bile Acid Diarrhea: From Molecular Mechanisms to Clinical Diagnosis and Treatment in the Era of Precision Medicine. <i>Int. J. Mol. Sci.</i> 2024, <i>25</i>, 1544
Anne-Marie Ellegaard, Martin L Kårhus, Filip K Knop
Expert Opinion on Investigational Drugs
|
March 12, 2011
Lixisenatide for type 2 diabetes mellitus
Mikkel Christensen, Filip K Knop, Tina Vilsbøll, et al.
Page
of 44
Search research articles
Search
Showing results (41-50 of 434) with videos related to
Sort By:
Page
of 44
Best Practice & Research. Clinical Endocrinology & Metabolism
|
September 15, 2009
The spectrum of antidiabetic actions of GLP-1 in patients with diabetes
Tina Vilsbøll, Jens J Holst, Filip K Knop
Expert Opinion on Drug Metabolism & Toxicology
|
October 26, 2012
GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations
Maria J Jespersen, Filip K Knop, Mikkel Christensen
Current Opinion in Endocrinology, Diabetes, and Obesity
|
January 23, 2022
Long-acting amylin analogues for the management of obesity
David S Mathiesen, Jonatan I Bagger, Filip K Knop
The Journal of Clinical Endocrinology and Metabolism
|
August 24, 2018
New Avenues in the Regulation of Gallbladder Motility-Implications for the Use of Glucagon-Like Peptide-Derived Drugs
Ida M Gether, Christina Nexøe-Larsen, Filip K Knop
Mayo Clinic Proceedings
|
January 9, 2018
The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes
Sofie Hædersdal, Asger Lund, Filip K Knop, et al.
Nature Reviews. Endocrinology
|
May 6, 2018
Glucagon-like peptide 1 in health and disease
Andreas Andersen, Asger Lund, Filip K Knop, et al.
Nature Reviews. Endocrinology
|
March 18, 2023
Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases
Sofie Hædersdal, Andreas Andersen, Filip K Knop, et al.
Frontiers in Endocrinology
|
December 3, 2021
Editorial: Proglucagon-Derived Peptides
Peter R Flatt, Filip K Knop, Andrei I Tarasov
International Journal of Molecular Sciences
|
August 10, 2024
Comment on Yang et al. Bile Acid Diarrhea: From Molecular Mechanisms to Clinical Diagnosis and Treatment in the Era of Precision Medicine. <i>Int. J. Mol. Sci.</i> 2024, <i>25</i>, 1544
Anne-Marie Ellegaard, Martin L Kårhus, Filip K Knop
Expert Opinion on Investigational Drugs
|
March 12, 2011
Lixisenatide for type 2 diabetes mellitus
Mikkel Christensen, Filip K Knop, Tina Vilsbøll, et al.
Page
of 44